Mutagenicity of 4-aminobiphenyl and 4-acetylaminobiphenyl in Salmonella typhimurium strains expressing different levels of N-acetyltransferase

Toxicology and Applied Pharmacology

Volumn 159, Issue 2, 1999, Pages 77-82

  Dang, Lanvi N ^a   McQueen, Charlene A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aromatic amines; Genotoxicity; N acetyltransferase

Indexed keywords

4 BIPHENYLAMINE; AMINOBIPHENYL DERIVATIVE; DNA; N (4 BIPHENYLYL)ACETAMIDE; TOBACCO SMOKE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; GENE; GENOTOXICITY; MOUSE; MUTAGENICITY; NONHUMAN; RAT; SALMONELLA TYPHIMURIUM;

EID: 0033200387     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8727     Document Type: Article

References (35)

1. Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. R., Michalek A. M., Laughlin R., Nemoto T., Gillenwater K. A., Harrington A. M., Shields P. G. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms and breast cancer risk. JAMA. 276:1996;1494-1501.
2. Bartsch H., Malaveille C., Friesen M., Kadlubar F. F., Vineis P. Black (air-cured) and blond (flue-cured) tobacco cancer risk IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur. J. Cancer. 29:1993;1199-1207.
3. Beland F. A., Beranek D. T., Dooley K. L., Heflich R. H., Kadlubar F. F. Arylamine-DNA adducts in vitro and in vivo; their role in bacterial mutagenesis and urinary bladder carcinogenesis. Environ. Health Perspect. 49:1983;125-134.
4. Brunborg G., Holme J. A., Alexander J., Becher G., Hongslo J. K. Genotoxic activity of the N-acetylated metabolites of the food mutagens 2-amino-3-methylimidazo[4,5f]quinoline (IQ) and 2-amino-3,8-dimethylimidazo[4,5f]quinoline (MeIQ). Mutagenesis. 3:1988;303-309.
5. PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U SA. 86:1989;7696-7700.
6. Cartwright R. A., Glashan R. W., Rogers H. J., Ahmad R. A., Barham-Hall D., Higgins E., Kahn M. A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacologenetic epidemiological approach to bladder cancer. Lancet. 2:1982;842-845.
7. Claxton J. D., Allen J., Auletta A., Mortelmans K., Nestmann F., Zieger E. Guide for the Salmonella typhimurium/mammalian microsome tests for bacterial mutagenicity. Mutat. Res. 189:1987;83-91.
8. Einisto P., Watanabe M., Ishidate M., Nohmi T. Mutagenicity of 30 chemicals in Salmonella typhimurium strains possessing different nitroreductase or O-acetyltransferase activities. Mutat. Res. 259:1991;95-102.
9. Flammang T. J., Kadlubar F. F. Acetyl coenzyme A-dependent metabolic activation of N-hydroxy-3,2′-dimethyl-4-aminobiphenyl and several carcinogenic N-hydroxy arylamines in relation to tissues and species differences, other acyl donors, and arylhydroxamic acid-dependent acetyltransferases. Carcinogenesis. 7:1986;919-926.
10. Flammang T. J., Yamazoe Y., Benson R. W., Roberts D. W., Potter D. W., Chu D. Z., Lang N. P., Kadlubar F. F. Arachidonic acid-dependent peroxidative activation of carcinogenic arylamines by extrahepatic human tissue microsomes. Cancer Res. 49:1989;1977-1982.
11. Glowinski I. B., Weber W. W., Fysh J. M., Vaught J. B., King C. M. Evidence that arylhydroxamic acid N,O-acyltransferase and the genetically polymorphic N-acetyltransferase are properties of the same enzyme in rabbit liver. J. Biol. Chem. 255:1980;7883-7890.
12. Hein D. W. Acetylator genotype and arylamine-induced carcinogenesis. Biochim. Biophys. Acta. 948:1988;37-66.
13. Hein D. W., Rustan T. D., Ferguson R. J., Doll M. A., Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch. Toxicol. 68:1994;129-133.
14. International Agency for Research on Cancer, 1987, IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Suppl. 7, World Health Organization, IARC, Lyon.
15. Ilett K. F., David B. M., Detchon P., Castledon W. M., Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res. 47:1987;1466-1469.
16. Kadlubar F. F., Beland F. A. Chemical properties of ultimate carcinogenic metabolites of arylamines and arylamides. Harvey R. G. Polycyclic Hydrocarbons and Carcinogenesis. 1985;175-276 American Chemical Society, Washington.
17. King C. M. Mechanism of reaction, tissue distribution, and inhibition of arylhydroxamic acid acyl transferase. Cancer Res. 34:1974;1503-1515.
18. King C. M., Glowinski I. B. Acetylation, deacetylation and acyltransfer. Environ. Health Perspect. 49:1983;43-50.
19. Lai C. C., Miller J. A., Miller E. C., Liem A. N-Sulfooxy-2-aminofluorene is the major ultimate electrophilic and carcinogenic metabolite of N-hydroxy-2-acetylaminofluorene in the livers of infant male C57Bl/6J × C3H/HeJ F1 (B6C3F1) mice. Carcinogenesis. 6:1985;1037-1045.
20. Lang N. P., Chu D. Z. J, Hunter C. F., Kendall D. C., Flammang T. J., Kadlubar F. F. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch. Surg. 121:1986;1259-1261.
21. Lang N. P., Butler M. A., Massengill J., Lawson M., Stotts R. C., Hauer-Jensen M., Kadlubar F. F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomarkers Prev. 3:1994;675-682.
22. Lemke L. E., McQueen C. A. Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine. Drug Metab. Dispos. 23:1995;559-565.
23. Maron D. M., Ames B. N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113:1983;173-215.
24. Mattano S. S., Land S., King C. M., Weber W. W. Purification and biochemical characterization of hepatic arylamine N-acetyltransferase from rapid and slow acetylator mice: Identity with arylhydroxamic acid N,O-acetyltransferase and N-hydroxylarylamine O-acetyltransferase. Mol. Pharm. 35:1989;599-609.
25. 6 to the mutagenic action of nitroarenes. Mutat. Res. 121:1983;17-23.
26. Miller J. A., Miller E. C. Some historical aspects of N-aryl carcinogens and their metabolic activation. Environ. Health Perspect. 49:1983;3-12.
27. Mommsen S., Barfod N. M., Aagaard J. N-acetyltransferase phenotypes in urinary bladder carcinogenesis of a low-risk population. Carcinogenesis. 6:1985;199-201.
28. Risch A., Wallace D. M. A., Bathers S., Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. 4:1995;231-236.
29. Smith B. J., DeBruin L., Josephy P. D., Eling T. E. Mutagenic activation of benzidine requires bacterial acetylation and subsequent conversion by prostaglandin H synthase to 4-nitro-4′-(acetylamino)biphenyl. Chem. Res. Toxicol. 5:1992;431-439.
30. Stevens G. J., LaVoie E. J., McQueen C. A. The role of acetylation in the mutagenicity of the antitumor agent, batracylin. Carcinogenesis. 17:1996;115-119.
31. Sugimura T., Nagao M. Modification of mutagenic activity. de Serres F. J., Mollander A. Chemical Mutagens. 1980;41-60 Plenum Press, New York.
32. Watanabe M., Ishidate M., Nohmi T. Sensitive method for the detection of mutagenic nitroarenes and aromatic amines: New derivatives of Salmonella typhimurium tester strains possessing elevated O-acetyltransferase levels. Mutat. Res. 234:1990;337-348.
33. Weber W. W. The Acetylator Genes and Drug Response. 1987;Oxford University Press, New York.
34. Weber W. W., Hein D. W. N-acetylation pharmacogenetics. Pharm. Rev. 37:1985;25-79.
35. Weeks C. E., Allaben W. T., Louie S. C., Lazear E. J., King C. M. N-hydroxy-N-2-fluorenylacetamide in Salmonella typhimurium. Cancer Res. 38:1978;613-618.